Elsevier launches case report-only surgery journal

Share this article:
Elsevier launches case report-only surgery journal
Elsevier launches case report-only surgery journal

Elsevier launched the International Journal of Surgery Case Reports (IJSCR), a new online journal dedicated exclusively to case reports.

The journal will serve as the companion to the International Journal of Surgery, and will be published eight times a year, in concert with its parent title. Submissions to the IJSC are peer-reviewed, although authors will have to pay almost $400 to publish their submissions, once accepted for publication.

Tom Reller, an Elsevier spokesperson, said the company has used the “author pays” model before, and IJSCR has already received approximately 50 submissions for review. A few IJSCR case reports have already been published in the company's Articles in Press category and included in the ScienceDirect online platform, and the first issue of the journal will publish “very shortly,” according to Reller. IJSCR will be distributed as an online-only title.

Drug and device advertising is not currently present in the journal, although Reller said the implementation of ads “is certainly a possibility going forward.” Reller said the number of case reports per issue has yet to be determined, but that Elsevier expects the number to increase steadily over time.

“While infrequently cited for research purposes, case reports are popular and represent some of the oldest levels of evidence,” said David Rosin, editor-in-chief, and Riaz Agha, managing director and executive editor, in a joint statement. Case reports include stories, anecdotes and patient-based learnings, and Elsevier hopes to raise their academic value by building a database of the reports, which “could be mined for interesting trends/patterns, disease modeling and for the purposes of surveillance, specially of rare diseases,” the statement said.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.